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Spinal cord injury (SCI) in dogs is commonly attributed to intervertebral disc extrusion
(IVDE). Over the last years substantial progress was made in the elucidation
of factors contributing to the pathogenesis of this common canine disease. A
detailed understanding of the underlying histopathological and molecular alterations
in the lesioned spinal cord represents a prerequisite to translate knowledge on
the time course of secondary injury processes into the clinical setting. This review
summarizes the current state of knowledge of the underlying pathology of canine
IVDE-related SCI. Pathological alterations in the spinal cord of dogs affected by
IVDE-related SCI include early and persisting axonal damage and glial responses,
dominated by phagocytic microglia/macrophages. These processes are paralleled
by a pro-inflammatory microenvironment with dysregulation of cytokines and matrix
metalloproteinases within the spinal cord. These data mirror findings from a clinical and
therapeutic perspective and can be used to identify biomarkers that are able to more
precisely predict the clinical outcome. The pathogenesis of progressive myelomalacia,
a devastating complication of SCI in dogs, is not understood in detail so far; however,
a fulminant and exaggerating secondary injury response with massive reactive oxygen
species formation seems to be involved in this unique neuropathological entity. There are
substantial gaps in the knowledge of pathological changes in IVDE with respect to more
advanced and chronic lesions and the potential involvement of demyelination. Moreover,
the role of microglia/macrophage polarization in IVDE-related SCI still remains to be
investigated. A close collaboration of clinical neurologists and veterinary pathologists
will help to facilitate an integrative approach to a more detailed understanding of the
molecular pathogenesis of canine IVDE and thus to identify therapeutic targets.
Keywords: spinal cord injury, IVDE, extrusion, macrophage, immunohistochemistry, axonal damage, macrophage
polarization, cytokine
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INTRODUCTION
Spinal cord injury (SCI) in dogs can be caused by either
extrinsic or intrinsic forces. Though extrinsic traumatic forces
such as road accidents, which make up the majority of human
cases of severe SCI, do also occur in pet dogs, intervertebral
disc extrusion (IVDE) is by far the most common cause
for SCI in dogs (1). IVDE-induced SCI accounts for up to
2% of all diseases in dogs (2–4) and represents one of the
most common diagnoses made by veterinary neurologists. In
a study conducted in Switzerland with a referral hospital
population of nearly 3,500 dogs with central nervous system
(CNS) diseases included, IVDE represented the most common
diagnosis, followed by epilepsy and other neurodegenerative
diseases (5).
Due to high standards in clinical management, the prognosis
of IVDE-induced SCI of mild to moderate severity is generally
good; however, 40–50% of dogs with severe SCI secondary to
IVDE (those who are paraplegic with absent nociception) do
not recover the ability to ambulate and may be euthanized
because of the condition, even with the highest standard of
care. The post-mortem examination of such cases provides
an opportunity to gain basic insights into the pathology and
pathogenetic basis of this clinically important disease. Besides
its doubtless high veterinary relevance, IVDE-induced SCI in
dogs moreover shares striking similarities with human traumatic
SCI (6). Similar to most cases of traumatic SCI in humans,
IVDE-induced SCI is caused by a relative contribution of
both compressive and contusive forces caused by structures
anatomically located ventral to the spinal cord (6–8). This
is in contrast to most experimental rodent models for SCI,
which commonly rely on purely concussive injuries caused
by dorsal weight drop or complete cord transection (6–9).
Moreover, compared to rodents, the canine spinal cord more
closely resembles the size of the human counterpart (8). Lastly,
and probably most important, canine IVDE is a spontaneous
disease with a high inter-individual variability (6, 7). Based
on these similarities, canine IVDE has developed into an
acknowledged translational animal model that may add the
missing heterogeneity to experimental investigations in rodent
models of SCI (6, 8). Consequently, veterinary clinical studies
in canine SCI may help to translate findings from experimental
rodent studies into the clinically relevant, naturally occurring
disease (7, 8, 10–12).
An enormous body of literature exists on themorphologic and
molecular pathology of experimental SCI, with comparatively
less data on naturally occurring cases of human SCI. It is
highly likely that canine IVDE-induced SCI shares many
of these pathological features reported in both human
traumatic SCI and experimental animal models. The present
summary focuses on data that have been gained in (histo-)
pathological studies on naturally occurring IVDE-induced SCI
in dogs, referring to only a few studies on experimental SCI,
where the knowledge of IVDE-induced canine SCI is only
fragmentary or absent. Starting with a brief overview on canine
intervertebral disc disease, the major focus of this paper is to
provide an overview of the pathologic events in the injured
canine spinal cord with reference to therapeutic implications
where applicable.
Basic Pathological Mechanisms of Canine
Intervertebral Disc Degeneration
Degeneration of the intervertebral disc is commonly the
prerequisite for later IVDE-induced SCI; i.e., IVD degeneration
represents an important predisposing factor for the disc
herniation into the vertebral canal. Early pioneer studies by
Hansen (1952) (13) have extensively described the pathological
changes during IVD degeneration and details of intervertebral
disc anatomy and degeneration are reviewed elsewhere in this
issue (Fenn et al.). Briefly, in chondrodystrophic dog breeds
such as the dachshund, beagle, and Pekingese, the nucleus
pulposus of multiple intervertebral discs undergoes progressive
chondroid metaplasia beginning in juvenile individuals (2,
6). Initial degenerative changes are completed as early as
1 year of age (2, 4). Due to their familial predisposition,
chondrodystrophic breeds are much more likely to develop
disc herniation than non-chondrodystrophic breeds, as they
are prone to premature senescence of the nucleus pulposus
(6, 14). Among chondrodystrophic breeeds, French Bulldogs
have gained enormously in popularity. Recent studies suggest
that French bulldogs are prone to various neurological diseases
with IVDE ranging on top of the neurological diseases in this
breed (15). In contrast to other breeds, cervical location of
IVDE seems to be more common in French bulldogs (15).
The reasons for the relatively high level of predisposition for
neurological diseases in this breed remain speculative; however,
besides chondrodystrophy, excessive inbreeding might represent
one factor that contributes to predisposition of French Bulldogs
to neurological disease development (15). For a more detailed
review of the genetic factors involved in canine IVDD the reader
is referred to Dickinson et al. in this edition. Recent independent
genome-wide association analyses for skeletal dysplasia and
IVDE identified a highly expressed FGF4 retrogene on CFA12,
which is associated with both IVDE and chondrodystrophy (16).
The nucleus pulposus is replaced by hyaline cartilage. The latter
progressively degenerates and calcifies in the late stage of IVD
degeneration (2, 17). In dachshunds with acute disc herniation,
histopathology reveals that the majority of extruded disc material
is calcified, even in the absence of radiographically visible
calcification (18). More recent histopathological studies propose
a grading scheme for intervertebral disc degeneration based
on an assortment of parameters. These include morphology of
the annulus fibrosus, chondrocyte metaplasia of the annulus
fibrosus, tears and cleft formations, chondrocyte proliferation
within the nucleus pulposus, presence of notochordal cells in
the nucleus pulposus, matrix staining of nucleus pulposus with
Alcian Blue/Picrosirius Red, endplate morphology, new bone
formation, and subchondral bone sclerosis (19). In this study,
glycosaminoglycan content and total histological score showed
high correlation.
In contrast to chondrodystrophic breeds, the intervertebral
disc of non-chondrodystrophic dogs has historically been
believed to undergo an age-dependent and slowly progressing
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fibroblastic metaplasia of both the annulus fibrosus and nucleus
pulposus (2, 4, 6), which may represent a non-hereditary wear-
and-tear-phenomenon. This traditional concept, i.e., chondroid
metaplasia of the nucleus pulposus in chondrodystrophic breeds,
and fibrous metaplasia in non-chondrodystrophic dogs, has
been recently been disputed by studies suggesting that IVDD
in chondrodystrophic and non-chondrodystrophic breeds is
more similar than previously believed (20). In fact, chondroid
metaplasia is observed in both chondrodystrophic and non-
chondrodystrophic dogs and fibrocytes were not seen in the
nucleus pulposus in any of the investigated discs in a recent
study, thus challenging this original “chondrodystrophic” and
“non-chondrodystrophic” paradigm in canine IVDD (20).
Clinical Spinal Cord Injury Caused by
Intervertebral Disc Herniation
The clinical presentation of IVDE in dogs spans a spectrum
ranging from neck or back pain to severe spinal cord injury with
loss of sensory and motor function caudal to the lesion. While
several clinical grading systems have been employed throughout
the literature to quantify severity of injury, the most commonly
used is a version of the modified Frankel scale. This scale
ranges from paraplegia with absent superficial and deep pain
sensation to normal dogs. Injury severity, as measured in this
way, correlates well with prognosis for recovery after surgical
decompression where dogs with grade 0 injuries experience
return of unassisted ambulation and fecal and urinary continence
in 50–60% of cases (21, 22).
The pathogenesis of canine IVD degeneration and IVDE has
been recently reviewed in detail (14) and is also covered in
detail in other articles in this issue. Using Hansen’s descriptors,
chondrodystrophic breeds are predisposed to Hansen type I
herniation (IVDE) whereas the non-chondrodystrophic breeds
are more prone to type II herniation (2, 17, 23). The vast majority
of research focusses on IVDE, as it is the most common type and
often induces the most severe lesions. Rapid extrusion of nucleus
pulposus results in compressive and contusive injury to the spinal
cord. Though IVDE induces a mixed contusive/compressive
force to the respective spinal cord segment (6–8, 14), the extent
of each varies both within the individual patient and with the
type of herniation observed. Since Hansen type I disc extrusions
typically occur acutely and with substantial force, they generally
cause considerably more severe trauma to the respective spinal
cord segments as compared to Hansen type II disc protrusions,
which are less severe and lead to more slowly developing forces
applied to the spinal cord (i.e., focus on the compressive part of
the force) (2, 6, 13, 14, 23).
In chondrodystrophic breeds, approximately 75% of
intervertebral disc herniations are found at the level of the Th 12
to L2 (13). Intervertebral disc herniations at the cervical level are
less common, accounting for approximately 14 to 35 percent of
all intervertebral disc herniations (4, 6, 23).
Some cases can clinically not be classified into either Hansen
type I or type II, as a proportion of non-chondrodystrophic
dogs may develop acute clinical signs with rapid onset, while
few dogs with Hansen type I herniation (extrusion) may develop
slowly progressing signs (14). Other types of herniation have been
described and besides the aforementioned forms, in which IVDE
is the sequela of IVD degeneration, non-degenerate physiological
disc material may be herniated into the vertebral canal and/or
spinal cord by extrinsic traumatic forces (traumatic disc prolapse)
(13, 14, 24). Various other forms of IVD disease are covered in
detail in the article of Fenn et al. in this Issue.
Irrespective of the exact type, herniation of the intervertebral
disc typically occurs in the dorsal direction, i.e., into the vertebral
canal (14). Monocytes and macrophages are found in extruded
disc material, and there is activation of extracellular signal-
regulated kinase p38 (25). Moreover, similar to IVDE in humans,
canine thoracolumbar IVDE is associated with elevated gene and
protein expression of key cytokines such as IL-6 and TNF-α and






Most of the data on pathological lesions in the spinal cord
derive from individuals with acute to subacute severe SCI
(paraplegic with and without pain perception, respectively),
with a considerable lack of histopathological descriptions on
more chronic lesions and less severe injuries, which is due
to the fact that, in a non-experimental set-up of studies
on a naturally occurring spontaneous disease, material for
histopathological investigations most commonly derives from
euthanized individuals with an acute onset of severe clinical
signs and a poor prognosis. Thus, pathological descriptions
are somewhat biased, and one should consider them mostly
mirroring extreme cases of a wide spectrum of time course and
lesion severity, respectively.
IVDE causes considerable, though highly variable,
pathological alterations within the respective spinal cord
segments and at distant sites within the neuraxis. Upon
necropsy, dorsal removal of vertebral laminae exposes the
vertebral canal and degenerate intervertebral disc material may
be detected within the vertebral canal in close proximity and
often firmly attached to the contused and compressed spinal
cord segment. Macroscopic alterations in the spinal cord itself
may range from no detectable changes, to discoloration, grossly
obvious hemorrhage, severe spinal cord and dural laceration,
or spinal cord atrophy in long standing cases. The histological
changes observed in dogs with IVDE-associated SCI are
relatively similar to histopathological alterations in spinal cords
of humans affected by SCI, underlining the role of canine IVDE
as a translational animal model that may allow extrapolation of
findings to naturally occurring human cases.
Histopathological alterations in the spinal cord of dogs with
SCI have been detailed as early as 1978 (26). In general, lesions are
highly variable, and may consist of variable degrees of necrosis
and hemorrhage in acute stages (26); Figure 1. Ultrastructurally,
hemorrhages, axonal spheroid formation, glial cell swelling,
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FIGURE 1 | Male Dachshund with type I intervertebral disc herniation (acute extrusion). Overview (right side) of HE stained spinal cord transversal section with
hemorrhage (he) accentuated within the gray matter and white matter malacia (ma). Inset upper left (A): moderate perivascular cuffing of mononuclear leukocytes and
focal disintegration of neuroparenchyma (necrosis, malacia). Inset lower left (B): moderate to severe white matter vacuolation within the ventrolateral funiculus,
characterized by multiple dilated myelin sheaths that contain hypereosinophilic swollen axons (spheroids). 20x magnification in insets.
white matter edema, and demyelination are observed in cases
of naturally occurring canine SCI (9). Moreover, remyelination
in the advanced disease by both oligodendrocytes and Schwann
cells was shown using electron microscopy (9). Depending on
the severity of the initial trauma, secondary injury processes
may finally culminate into liquefactive necrosis (malacia) of the
spinal cord segment and glial scarring with variable involvement
of neuroparenchymal cavitation and cyst formation. Chronic
intramedullary lesions/cavitations are associated with severe
initial SCI and negative clinical outcome (27). Ascending and
descending myelomalacia is a devastating complication in a
proportion of dogs with SCI and will be discussed at the end of
this chapter.
Clinical neurological grades of dogs affected by thoracolumbar
IVDE-induced SCI correlate with the extent of white matter
damage (28). Of interest, however, is the notable observation that
clinical injury severity does not always correlate with severity
of histopathologic lesions, underscoring the need for further
studies of pathological features of canine IVDE-induced SCI (28).
Additionally, some clinical signs such as duration of clinical
signs, Schiff-Sherrington posture, loss of reflexes and pain on
spinal palpation are not associated with the histopathological
severity of spinal cord damage (28). These results suggest
that some clinical signs are rather associated with functional
neurological disturbances such as conduction block due to
energy depletion or failure, that are not necessarily reflected by
histopathological alterations.
Thus, both the immune response and axonal pathology are
pivotal hallmarks of SCI (6). Consequently, these pathogenetic
factors have been proposed to serve as major targets for
future therapies (6, 29–32) and a detailed understanding of
the underlying pathology during canine IVDE-induced SCI
is a basis essential to the development of such therapeutic
interventions (6).
Axonal and Myelin Pathology in Canine
IVDE-Induced SCI
Axonal damage is a central hallmark of all forms of endogenous
or exogenous traumatic CNS injury and various studies have
characterized the underlying molecular pathogenesis of axonal
degeneration and regeneration in traumatic brain and spinal
cord injury in detail (33). As axonal damage may be the
most obvious pathological correlate of clinical motor deficits,
it is not surprising that axonal damage is a consistent
histopathological feature of canine IVDE-induced SCI. In
histopathology, axonal damage generally appears as axonal
swelling and the occurrence of hypereosinophilic spherical
enlarged axons (spheroids, Figure 1) within dilated myelin
sheaths. Sharing many pathogenetic features with Wallerian
degeneration, axonal damage is not restricted to the lesion center
at the site of disc herniation but may also be seen in various spinal
cord segments cranial and caudal to the initial lesion site.
Ultrastructurally, axoplasmic changes in spinal cords from
dogs suffering from IVDE-induced SCI are relatively similar to
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the ultrastructural axonal changes seen in experimental SCI in
rodents and monkeys (9, 34–39). Following compressive injury
to the spinal cord in rats there is periaxonal space formation,
myelin disruption and granular disintegration of neurofilaments
(35). Moreover, organelle accumulation and giant axons may
occur (35). Contusion SCI in rhesus monkeys similarly leads
to axonal accumulation of dense bodies, vesicular structures,
multivesicular bodies, and organelles (36). Axoplasmic vesicles,
mitochondria, and electron-dense bodies are observed within
reactive axonal enlargements (37). Though variable, all of the
above mentioned features are also observed ultrastructurally in
dogs with IVDE-induced SCI (6, 9, 34).
Deficits in both fast anterograde axonal transport mechanisms
and axonal neurofilament phosphorylation have been implicated
in the pathogenesis of axonal damage in canine IVDE-induced
SCI (6, 34). Using immunohistochemistry, β-amyloid precursor
protein (APP) is not detectable in healthy axons due to fast
axonal transport under physiological circumstances. However,
there is fast accumulation of APP, if axonal transport is disturbed
due to pathological conditions (40). Consequently, APP is a
well-established immunohistological marker for axonal damage
and has been previously used to detect damaged axons in
experimental SCI in dogs caused by inflated angioplasty balloons,
where its expression correlates with severity and duration of
compression (41, 42). Similarly, experimental SCI in rodents and
spontaneous SCI in people are both associated with strong axonal
expression of APP (43–45).
In dogs with naturally occurring IVDE-induced SCI, APP is
detectable in the lesion epicenter of both acutely and subacutely
injured dogs (Figure 2) (6, 34). However, axonal APP expression
can also be observed up to 3 cm caudal to the lesion epicenter
during the subacute phase of injury, suggesting progressive
spatial spread of disturbances in fast axonal transport (6, 34).
Similarly, experimental rodent models and naturally occurring
SCI in people leads to axonal APP-expression distant to the lesion
epicenter (43, 45). These findings indicate that axonopathy is
not simply and solely attributed to the initial primary injury but
rather a timely and spatially progressive phenomenon reflecting
secondary injury mechanisms (6).
In parallel to axonal APP-immunoreactivity, previous
immunohistochemical studies on canine IVDE-induced SCI
revealed enhanced axonal expression of non-phosphorylated
neurofilaments (n-NF) in axons of dogs with acute and subacute
SCI (6, 34); Figure 2. Moreover, similar to APP, n-NF-expression
has been noted in axons several centimeters apart from the
lesion center (34). However, in contrast to APP, which is
mainly detected in swollen axons, n-NF immunopositivity was
also seen in several axons with normal diameters (Figure 2)
(6, 34). This implies that both markers might label, at least in
part, distinct axonal pathological processes (6). In traumatic
brain injury in rats, neurofilament compaction in axons has
previously been reported to occur independently from APP-
immunoreactivity (46). Thus, neurofilament alterations and
disturbed axoplasmic transport might in part represent differing
pathological phenomena (6).
In addition to traumatic CNS injury, enhanced axonal n-NF
and APP-expression has been demonstrated in several animal
models of demyelinating disease in various species including
some dog studies (47–50), suggesting that altered neurofilament
phosphorylation and disturbances in fast axonal transport
represent conserved phenomena of axonopathy irrespective of
the underlying disease entity.
Though axonal damage predominates, evidence for intrinsic
axonal regeneration attempts has been reported in dogs with
IVDE-induced SCI in terms of axonal expression of growth-
associated protein 43 (GAP-43) (34). GAP-43 immunoreactivity
was noted in a small proportion of axons in dogs with acute
and subacute SCI, which vas verified by immune-electron
microscopy. Ultrastructurally, immunoreaction was noted in
swollen axons lacking dense body accumulation, but filled with
large numbers of mitochondria (34). Axons express GAP-43
during development and regeneration (51). Live imaging on
individual axons in experimental SCI have shown early axonal
regeneration attempts (52); however, functional restoration
seems to be insufficient. It is proposed that regenerating
axons during SCI may fail to navigate to a proper target
(52). This might in part be attributed to the expression of
regeneration-inhibiting molecules such as Nogo and MAG, and
pharmacological modulation of these molecules is believed to
represent a promising target to facilitate axonal regeneration
in terms of functional restoration (53, 54). Several further
experimental therapeutic approaches aim to facilitate these
intrinsic regenerative responses (29). In fact, transplanting
regeneration promoting cells into the spinal cord of rodents with
SCI has shown to enhance axonal GAP-43 immunoreactivity,
which was associated with an improved clinical outcome
(55–57). Moreover, facilitation of alternatively activated anti-
inflammatory macrophages is paralleled by increased axonal
expression of GAP-43 and improved locomotor recovery in
spinal cord lesioned mice (58).
Myelin pathology, though a focus of experimental SCI work,
has not been extensively reported in canine SCI. Though there
is reduced immunoreactivity of myelin basic protein (MBP)
in the white matter of dogs with subacute IVDE-induced
SCI (34), this has rather been attributed to myelin edema
and myelin sheath swelling than true demyelination. In an
ultrastructural study of canine SCI, including various causes such
as fractures, subluxations, and IVDE, demyelinated axons were
observed within 2 weeks after initial injury and, interestingly, in
advanced disease stages, both Schwann cell and oligodendrocyte
remyelination was observed (9). Moreover, subtle partial and
paranodal myelin abnormalities were seen ultrastructurally. This
evidence for delayed myelin loss in canine IVDE-induced SCI
is mirrors the situation in human spinal cord injury. Naturally
occurring SCI in humans is associated with delayed and long-
lasting myelin loss (59, 60). Morphologically detectable myelin
abnormalities are generally observed subsequent to early axonal
damage, thus recapitulating the principle processes during
Wallerian degeneration. Moreover, demyelination in canine
SCI might in part also reflect pathomechanisms referred to
as the “inside-out theory” in neurodegenerative diseases (6,
61). Though this concept is controversial, it suggests that
axonal damage functions as a mechanism triggering secondary
demyelination (47, 61). Several lines of evidence indicate
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FIGURE 2 | Male Dachshund with type I intervertebral disc herniation (acute extrusion). Immunohistochemical detection of axonal damage. (A) Beta-APP
accumulates within swollen axons indicating disruption of the fast axonal transport machinery. (B) Non-phosphorylated neurofilament (nNF), another marker for axonal
damage, is detected within numerous swollen axons but is also expressed by axons with a normal appearing diameter. 40x magnification.
similarities in terms of this triggering function of primary
axonopathy between neurodegenerative and viral CNS diseases
on the one side and SCI on the other side (6, 61). In a clinical
context, dogs with thoracolumbar IVDE with loss of ambulation
had higher MBP concentration within the CSF compared with
control dogs, suggesting that elevated MBP levels within the CSF
are associated with poor clinical outcome (62).
Based on the assumption that demyelination is an event
that occurs relatively late in the progress of secondary injury,
investigations on chronic cases of canine IVDE-induced SCI
are urgently needed. Evidence that demyelination does occur
in chronically injured dogs is for instance based on clinical
trials. 4-Aminopyridine (4-AP) is a compound known to improve
function in demyelinating conditions. Dogs with spinal cord
injury treated with 4-AP show significant improvement in
supported stepping scores (63) suggesting that demyelination
plays a role in advanced and long standing cases. As mentioned
above, pathological data on naturally occurring canine SCI are
primarily based on dogs with acute to subacute IVDE-induced
SCI but there is little information upon the histopathology of
chronic cases (14, 64). Similar to experimental data and lesion
pathology in human SCI, chronic cases of canine IVDE-induced
SCI are characterized by progressive white and gray matter loss
with or without cyst formation and progressive replacement
by extensive gliosis (14). In an MRI-study on chronic SCI in
dogs, intramedullary cavitation and cyst formation was reported
(27). Histopathologically, chronic lesions were characterized by
gray matter-accentuated malacia, severe gliosis, and variable
infiltration of phagocytic gitter cells (27). Multiple axonal
spheroids can be detected, suggesting ongoing axonal damage.
Myelin sheaths within the white matter showed dilatation
and occasional myelinophages within dilated myelin sheaths.
Some cases exhibited pan-myelomalacia with complete loss of
organotypic structure, replaced by diffuse extensive gliosis (27).
Mirroring overall neuroparenchymal loss of both gray and
white matter, macroscopic changes of the chronically injured
canine spinal cord may include hour-glass shaped atrophy of the
respective spinal cord segment (27). Similarly, in experimentally
induced SCI in dogs histological analyses at 12 weeks after SCI
revealed amorphous cavities in the gray matter with spread to the
white matter with caudally accentuated spatial spread up to 1 cm
apart from the epicenter (65).
Inflammation and Glial Cell Reactions in
Canine IVDE-Induced SCI
In severe acute cases of canine SCI, the first cell type that arises
are neutrophils, and increased cell numbers of neutrophils are
commonly detected within the CSF of dogs with IVDE-induced
SCI. Histopathologically, neutrophils are commonly associated
with areas of hemorrhage (66). In parallel, there is infiltration of
MAC-387-positive monocyte-derived macrophages and variable
perivascular leukocyte cuffing (Figures 1, 3). Cellular reactive
changes begin to be more obvious in subacute cases, in
which there is a phagocytic response that is impressively
dominated by microglia/macrophages (66). MHC class II
expressing microglia/macrophages have also been reported as
the predominating cell type in human SCI (Figure 3) (67),
whereas lymphocytes seem to play a subordinate role (67,
68). In dogs, microglial cells have been analyzed in detail in
various neurological diseases such as canine distemper virus
infection and SCI (11, 69, 70). In healthy dogs, canine microglia
derived from the spinal cord show a relatively higher capacity of
phagocytosis and generation of reactive oxygen species (ROS) as
compared to cells derived from the healthy brain (70). Dogs with
SCI reveal enhanced microglial expression of surface molecules
such as B7-1, B7-2, MHC class II, CD1c, ICAM 1, CD14,
CD44, and CD45, as determined by flow cytometry (11). Besides,
phagocytosis and ROS generation of microglia are elevated in
dogs with SCI (11).
Extensive research on microglia/macrophages is similarly
done in experimental laboratory studies of SCI and manipulation
of the response of these cells is regarded as a promising
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FIGURE 3 | Male Dachshund with type I intervertebral disc herniation (acute extrusion). Immunohistochemical detection of macrophages, which are a dominating
immune cell population involved in secondary injury mechanisms. (A) Mac387, a clone that detects myleoid/histiocyte antigen, only detects relatively few,
monocyte-like blood born macrophages. (B) There is severe up-regulation of MHC class II on phagocytic gitter cells. (C) Similarly, Iba-1, a pan-macrophage marker,
labels numerous phagocytic microglia/macrophages within the affected white matter. (D) CD204, a marker that has been proposed to mainly detect M2-polarized
macrophages, labels several microglia/macrophages within the white matter and within dilated, optically empty myelin sheaths (myelinophagia). 40x magnification.
field in the development of new therapeutic approaches.
Based on a relatively novel basic, but very simplified concept
that microglia/macrophages may be polarized into either
pro-inflammatory and neurotoxic (M1-) cells or alternatively
activated, anti-inflammatory and regeneration promoting (M2-)
cells, a bulk of experimental research has been conducted
focusing on the role of these cells in SCI. Pioneer studies on
rodent SCI revealed that SCI is characterized by an early and
persisting M1-dominated macrophage response (71). The fact
that this polarized M1-response overwhelms a relatively sparse
M2-macrophage response has led to the idea that shifting this
phenomenon toward a regeneration-promoting M2-dominated
response might be a rewarding research target for therapies in
SCI (71).
Whether this macrophage polarization also occurs in the
context of clinically relevant naturally occurring canine SCI has
not been investigated to date. However, several lines of evidence
indicate that the microglia/macrophage response is similarly
associated with a polarization of macrophages toward a pro-
inflammatory phenotype. Subacute canine IVDE-induced SCI
is associated with a dominating response of MHC class II-
expressing phagocytic microglia/macrophages that is paralleled
by a pro-inflammatory microenvironment (66, 72). Moreover,
microglia/macrophages are a pivotal source of ROS, tissue
degrading metalloproteinases and neurotoxic mediators.
Detection of M1- and M2-macrophages in situ relies on
immunohistochemical markers and there is a well-established
panel of such antibodies for the distinctive detection of
these cells in laboratory rodent tissue. However, the markers
routinely used for the detection of rodent M1- and M2-
macrophages cannot simply be transferred to other species.
The nitric oxide and arginase metabolism of macrophages is a
commonly used basis for the detection of rodent M1- and M2
macrophages. Consequently, arginase (Arg)1 and inducible nitric
oxide synthase (iNOS) are the prototype markers to detect rodent
M2 and M1-macrophages in tissue sections, respectively (71).
However, there are considerable species differences, especially
in the context of NO metabolism of macrophages and these
well-established markers are not necessarily adequate to detect
human and canine macrophages (73). Thus, development of
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a panel of antibodies that enables the detection of canine
M1- and M2-macrophages in tissue sections is highly needed.
Recently, canine polarized macrophages have been characterized
in vitro. Unstimulated (M0), M1- (GM-CSF, LPS, IFNγ-
stimulated) and M2- (M-CSF, IL-4-stimulated)-polarized canine
blood-derived macrophages showed distinct ultrastructural
morphologies (73, 74). Interestingly, immunofluorescence using
standard literature-based prototype-antibodies against CD16,
CD32, iNOS, MHC class II for the detection of M1-macrophages
and CD163, CD206, and arginase-1 for the detection of
M2-macrophages demonstrated that solely CD206 was an
appropriate marker that discriminated M2-macrophages from
both other phenotypes (73, 74). In the same study, a global
microarray analysis was performed and revealed changes in
the transcriptome of polarized canine macrophages and similar
to the results on the protein level, there were only minor
overlaps in the gene sets of the dog compared to prototype
markers of murine and human macrophages (73, 74). The
transcriptome data of these canine macrophages might represent
a basis for the subsequent development of immunohistochemical
markers for the distinction between canine M1- and M2-
macrophages, respectively, that are highly needed to classify the
microglia/macrophage phenotype in the naturally injured canine
spinal cord.
As mentioned above, data on naturally occurring chronic
IVDE-induced lesions are extremely sparse. Glial scar formation
is a common finding in experimental and naturally occurring
human SCI. Similarly, extensive glial proliferation (gliosis) has
been reported in dogs with chronic IVDE-induced SCI (27).
Experimental SCI in dogs 12 weeks post injury is similarly
characterized by severe astrogliosis as revealed by enhanced
immunoreactivity for GFAP with spatial spread, mainly in the
caudal direction (65).
Ependymal cells have recently been highlighted to participate
in the cellular reaction following canine SCI. Due to its function
as a source for neural precursors the spinal ependymal layer
is believed to possess regenerative capacity and consequently
represents another field of growing research, especially in
the context of SCI (75, 76). Immunohistochemistry revealed
increased numbers of GFAP-positive cells in acute IVDE-induced
SCI in dogs with SCI at the lesion epicenter and additionally
at sites proximal to the lesion center (76). It is proposed that
the spinal ependymal layer may have the capacity of astrocytic
differentiation during naturally occurring SCI in dogs. Besides
enhanced GFAP-immunoreactivity of the spinal ependymal layer,
acute IVDE-induced SCI is also characterized by altered E-
cadherin expression patterns, indicating that a loss of cellular
polarity could promote ependymal cell migration to the injury
site (76).
The Need for Non-invasive Biomarkers in
Canine IVDE Induced SCI
From a clinical perspective, a non-invasive biomarker that is
able to predict clinical outcome, particularly in dogs with the
most severe SCI, is highly needed. Multiple studies have assessed
molecules in the CSF or serum, based on the hypothesis that
the concentration of such metabolites is associated with injury
severity and outcome, respectively. The results of these studies
are also interesting from a pathological point of view, as clinically
detected elevated levels of serum and CSF molecules may also
be assessed in pathological analyses on post-mortem tissue
such as immunohistochemistry and RT-qPCR methods. Vice
versa, evidence from pathological studies may be extrapolated to
clinical settings as enhanced expression of molecules detected via
histopathological methods or molecular biology on post mortem
tissue might develop new hypotheses in the search for novel
biomarkers in a clinical setting. Thus, research on biomarkers for
IVDE-induced SCI is an interesting field in which pathology and
clinical neurology obviously benefit from each other.
Previously assessed candidate biomarkers in canine
IVDE-induced SCI in CSF and serum, respectively, include
metalloproteinases, neuronal/axonal cytoskeletal molecules,
inflammatory cell counts, acute phase proteins, cytokines,
arachidonic acid metabolites, and glial cytoskeletal components.
Enhanced MMP-9 activity in the CSF of the lumbar spine has
been reported to indicate severe SCI with poor prognosis (77).
Similarly, microtubule-associated protein tau, detected by ELISA
in cisternal CSF, is associated with unsuccessful outcome in
paraplegic dogs suffering from thoracolumbar or cervical IVDE
(78). Serum levels of phosphorylated neurofilament heavy chain
(pNF-H) are associated with severity of thoracolumbar IVDE and
may predict an unfavorable prognosis (79). Increased cisternal
CSF total nucleated cell count correlates with injury severity;
however, the investigated CSF characteristics did not differentiate
IVDE-induced SCI from other spinal cord diseases (80). The CSF
concentrations of the acute phase proteins C-reactive protein and
haptoglobin are associated with IVDE-induced injury severity;
however, not correlating with 42 d motor outcome (81). The
concentration of the arachidonic acid metabolites PLA2 and
PGE2 in the CSF are higher in dogs with SCI compared to control
dogs, while LCT4 concentration is lower in dogs with SCI than
that in control dogs (82). Moreover, the concentration of PGE2
positively correlates with increased severity of SCI. Within the
1st days of IVDE-induced SCI, serum levels of GFAP and S100β
rapidly rise, while pNF-H showed a later peak at 14 days post
injury (83). Moreover, serum GFAP levels during the first 3 days
can be used as a biomarker to predict recovery in severe SCI (83).
Matrix Metalloproteinases in Canine
IVDE-Induced SCI
Matrix metalloproteinases (MMPs) have been shown to
participate in the pathogenesis of canine IVDE-induced
SCI in several studies. MMPs play a pleiotropic role in
various neurologic diseases. They are involved in both axonal
degeneration and regrowth and their signaling is crucial for
postinjury reorganization and synaptic stabilization (84). Besides,
MMPs are pivotal mediators of secondary injury and promote
disruption of the blood-brain and blood-spinal cord barrier
(84). In parallel, their signaling is necessary for healing processes
such as angiogenesis, but on the other hand MMP expression
promotes formation of a regeneration-inhibitory glial scar. Thus,
MMPs play an important pathogenetic role during SCI.
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Especially, the gelatinases MMP-2 and MMP-9 show time-
dependent expression during SCI in both experimental and
naturally occurring SCI (68). MMP-9 knock-out mice show less
expression of regeneration inhibiting molecules when compared
to wild-type mice with SCI (85). MMP-9 has thus gained much
attention as a therapy target, as modulation of its expression
might reduce glial scarring following SCI (85). In acute
human SCI, MMP-9 is expressed by neutrophils in areas with
hemorrhage as revealed by immunohistochemistry (68). Rapidly
enhanced expression ofMMP-9 in experimental contusion SCI in
rodents is associated with an inappropriate function of the blood-
spinal cord barrier as well as in inflammation and locomotor
recovery (86). Compared to wild type mice, there is improved
locomotor recovery in MMP-9 knock-out mice (86, 87).
Following experimental SCI in rodents, there is also
upregulation of MMP-2. However, this upregulation is delayed
when compared to MMP-9 (88, 89). In contrast to MMP-
9, deficiency in the expression of MMP-2 is associated with
impairment of locomotion in experimental SCI in mice (88).
Thus, it is proposed that MMP-2 rather plays a beneficial role
following SCI, in part by at regulating function that seems to
target axonal plasticity and white matter sparing (88).
Dysregulation of the gelatinases MMP-2 andMMP-9 has been
reported in previous studies on canine IVDE-induced SCI by
means of RT-qPCR on spinal cord tissue of dogs (6, 34). While
MMP-9 transcripts were up-regulated in dogs with acute SCI,
MMP-2 exhibited a transient downregulation in the acute disease
phase as compared to spinal cord tissue of neurologically healthy
dogs (6, 34). Similarly, MMP-9 activity is increased in the CSF
and serum of dogs with acute IVDD as revealed by zymography
(90). Interestingly, elevated MMP-9 levels are associated with a
poor outcome in dogs with IVDE-induced SCI (77, 90). Based
on these observations and the hypothesis of a detrimental role
of early MMP-9 signaling in dogs with IVDE-induced SCI, a
randomized, blinded, placebo-controlled study was initiated to
assess efficacy of the broad spectrum MMP-inhibitor GM6001
(91). In this study, dogs received GM6001 dissolved in dimethyl
sulfoxide (DMSO), DMSO alone, or saline. GM6001 reduced
serum MMP-9 activity compared to the other two groups
(91). Interestingly, dogs treated with saline had significantly
lower functional scores than dogs receiving DMSO or GM6001,
demonstrating that there was no independent effect of GM6001
(91). The authors conclude that DMSO might have therapeutic
effects in the acutely injured spinal cord. Similarly, recent clinical
trials using the same agent, GM6001, demonstrated higher
bladder compliance in dogs treated with GM6001 and DMSO
as compared to controls (92). However, there were transient
greater adverse events in GM6001-treated dogs compared to
those treated with the vehicle control, and again, there was no
difference in motor scores between dogs treated with GM6001
and DMSO vs. dogs treated with DMSO alone (92).
Cytokines in Canine IVDE-Induced SCI
The cerebrospinal fluid of dogs with acute, surgically treated,
thoracolumbar IVDE has been assessed regarding expression
of interleukin (IL)-2,−6,−7,−8,−10,−15,−18, granulocyte
macrophage colony stimulating factor (GMCSF), interferon
gamma (IFN-γ), keratinocyte chemoattractant-like (KC-
like) protein, IFN-γ-inducible protein-10 (IP-10), monocyte
chemotactic protein-1 (MCP-1), and tumor necrosis factor
alpha (TNF-α) (93). Using a bioplex system, IL-8 concentration
was found to be significantly higher in SCI cases than healthy
controls and negatively correlated with the duration of SCI
(93). Moreover, the MCP-1 concentration demonstrated to be
negatively associated with 42-days post-injury outcome (93).
Similarly, an early upregulation of pro-inflammatory cytokine
mRNA (IL-6, IL-8 and TNF) has been noted in spinal cord
tissue of dogs with acute IVDE-induced SCI (1–4 days post
IVDE) using RT-qPCR of mRNA extracted from affected spinal
cord tissue (66). IL-8 mRNA upregulation was also found in
dogs with more than 4 days post IVDE suggesting a prolonged
role of this pro-inflammatory cytokine in the pathogenesis of
canine IVDE-induced SCI (66, 93). While IL-10 showed no
differences in expression in either control dogs or dogs with SCI,
expression of TGF-β showed up-regulation exclusively in spinal
cord tissue of dogs with subacute SCI for more than 4 days. It is
concluded that acute IVDE-induced SCI in dogs is dominated by
a pro-inflammatory microenvironment (66, 72). The previous
findings on cytokine expression in canine IVDE-induced SCI
largely mirror findings in human cases of SCI and experimental
SCI in rodents. For instance, several pro-inflammatory cytokines
including IL-6 and IL-8 have also been reported to be upregulated
in the CSF of humans affected by SCI (94). Interestingly, IL-8
levels within the CSF of people with SCI positively correlate with
injury severity (94, 95). The delayed expression of TGF-β in dogs
with IVDE-induced SCI is in concordance with experimental SCI
in rats (96). TGF-β reduces the lesion volume and is associated
with decreased numbers of macrophages in experimental rat SCI
(96, 97)
Taken together, there is dysregulated cytokine expression
with a lack or delay of anti-inflammatory cytokines and a
dominance of pro-inflammatory cytokines during acute canine
IVDE-induced SCI. These factors are thus believed to contribute
to the lesion development and secondary injury processes in
canine IVDE-induced SCI (6).
Further demonstrating that pro-inflammatory processes
predominate in acute IVDE-induced SCI in dogs, there
is significant dysregulation of acute phase proteins in the
CSF of dogs with IVDE-induced SCI. Concentrations of C-
reactive protein (CRP), haptoglobin (Hp), alpha-1-glycoprotein,
and serum amyloid A were measured in a previous study
(81). Interestingly, compared with healthy control dogs, Hp
concentrations were higher in the CSF of affected dogs (81).
Moreover, the authors reported that higher concentrations of
CRP and Hp were associated the severity of injury; however,




A small but significant proportion of dogs affected by IVDE may
develop one of the most disastrous complications, progressive
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FIGURE 4 | Male 6 years old Yorkshire Terrier with progressive myelomalacia (PMM) following acute intervertebral disc extrusion. In PMM the shown lesions are not
restricted to the initial site of spinal cord injury but extend several centimeters into cranial and caudal direction (ascending and descending malacia). (A) Gross picture
of a transversal section of the formalin fixed spinal cord with complete disintegration of spinal cord neuroparenchyma and hemorrhage. (B) The HE stained overview of
the transversal section shows polio- and leukomyelomalacia with complete loss of cellular details and loss of distinction between white and gray matter. (C) Multiple
foamy microglia/macrophages labeled by the lectin of Bandeiraea simplicifolia 1 have infiltrated the lesion and remove cellular debris. 40x magnification. (D) There is
severe extravasation of erythrocytes within the white and gray matter (hemorrhage), associated with infiltration of viable and degenerate neutrophils adjacent to areas
of white matter damage with spheroids and myelin vacuolation. 10x magnification.
myelomalacia [PMM; (98)]. PMM is a unique entity, observed
in both humans and dogs with severe injuries to the spinal
cord and distinct from the initial SCI event. Though PMM can
be observed following various forms of SCI including external
trauma such as fractures, IVDE represents the most common
initial type of SCI in dogs with subsequent PMM. The condition
is characterized by progressive hemorrhagic necrosis of the spinal
cord that diffusely ascends and/or descends over many spinal
cord segments (99). PMM often develops early during the time
course of IVDE and most dogs with PMM are euthanized within
3 days after onset of signs due to progressive respiratory paralysis
(100). Considerable efforts have been undertaken to identify risk
factors that are associated with this typically fatal condition. The
prevalence of PMM is as low as 2% in the overall dog population
with thoracolumbar IVDE, but severely elevated in paraplegic
dogs that lack pain perception (101). In fact, the prevalence
of PMM rises up to 10–12% in paraplegic dogs with absent
deep nociception (21, 102). It appears that French Bulldogs
may possess a breed predisposition to develop the devastating
condition and the condition is more commonly diagnosed in
dogs with extensive hyperintensity of the spinal cord on T2
weighedmagnetic resonance imaging, dogs< 6 years of age, dogs
with L5-6 disc herniations, and dogs with a rapidly progressive
onset of clinical signs (103). A comprehensive recent study on 45
dogs with PMM identified IVDE at the lumbar intumescence as a
strong risk factor that was associated with PMM (104). Moreover,
surgery performed more than 12 h after loss of ambulation was
also positively and treatment with corticosteroids was negatively
associated with the development of PMM (104). Serum levels
of GFAP have also been proposed as a biomarker for PMM. In
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one study, of which seven dogs had detectable levels of serum
GFAP, 6 developed PMM (105). Sensitivity and specificity of
the GFAP to predict PMM were reported to be 75 and 97.7%,
respectively (105).
While there have been some advances in the identification
of risk factors associated with the disease, knowledge on the
pathogenesis of PMM is strikingly sparse. In a histologic study,
endothelin-1 (ET-1) immunoreactivity was noted in astrocytes,
macrophages, and neurons, but only rarely in endothelial cells
(106). At the lesion epicenter of spinal cord hemorrhage, ET-
1 immunoreactivity was significantly higher in astrocytes and
lower in neurons than in non-affected control dogs. Moreover,
there was higher astrocytic and neuronal ET-1 immunoreactivity
in spinal cord segments remote from the epicenter than in the
center itself. The authors conclude that elevated ET-1 expression
over multiple spinal cord segments after IVDEmight be involved
in the pathogenesis of PMM (106).
Histopathologic alterations of PMM are generally
characterized by severe liquefactive necrosis of the spinal
cord that extends over several segments (Figure 4). It is
proposed that PMM represents a form of exuberant and
dysregulated secondary injury response (99). The affected
spinal cord tissue shows extensive hemorrhage and necrosis in
both the gray and white matter with disruption of myelin and
necrotic and chromatolytic neurons as well as prominent swollen
endothelial cells lining remaining blood vessels (Figure 4)
(99). Parenchymal and meningeal blood vessels have been
reported to be necrotic with perivascular deposition of fibrin
(98). Moreover, some vessels may contain thrombi (98). Severe
lesions are characterized by an amorphous mixture of tissue
debris, macrophages, and blood (106). Variably, intervertebral
disc material may be detected in proximity to the meninges. The
necrotic processes are accompanied by a reactive inflammatory
response with neutrophils predominating due to the acute
nature of the pathologic alterations. Moreover, lesions are
characterized by infiltration of CD18-positive phagocytic
microglia/macrophages (99). Hemorrhagic and necrotic debris
may also be detected within the central canal in spinal cord
segments remote from the lesion epicenter (107). In fact,
intramedullary and subdural hemorrhages are significantly
associated with the degree of white and gray matter damage, and
the progressive nature of PMM is in part thought to be linked to
high intramedullary pressure (107).
Oxidative stress is proposed to be involved in the pathogenesis
of PMM, evidenced by the fact that PMM is associated with
elevated levels of 8-isoprostanes and acrolein with concurrent
reduction in endogenous anti-oxidation of glutathione in the CSF
and urine of dogs suffering from the disease (99). The authors
propose that the pathological condition of PMM represents an
extreme case of secondary injury, in which the physiological
defense systems are unable to terminate the progression of
oxidative injury (99). Moreover, decreased anti-oxidation is
associated with increased phagocytosis at the lesion center
(99), suggesting that macrophages that occur during PMM
might play a detrimental role in the process. The role of
macrophages, and especially their potential polarization toward
a neurotoxic phenotype, has not been addressed in detail so
far and might represent a promising field for future studies.
However, infiltration of neutrophils and macrophages has so far
been regarded as a bystander phenomenon, that is not initiating
the progression of PMM by itself (99).
CONCLUSIONS AND FUTURE
DIRECTIONS
Conclusively, in parallel to the ongoing and growing focus on
IVDE as a translational clinical animal model for SCI, there
is a growing number of publications, investigating pathologic
processes that occur following herniation of the intervertebral
disc into the vertebral canal. Morphologic, axonal, glial and
immune responses largely mirror changes seen in other animal
models for SCI and the human disease; however, despite its
high prevalence in veterinary clinical neurology, relatively little is
known on the exact time course of secondary injury processes in
the canine spinal cord affected by SCI. As immune processes, and
here, especially the role of microglia/macrophages, is a rapidly
growing field of experimental SCI research and a promising
target for novel therapeutic approaches, further focus on the
role of this cell population in this clinically relevant SCI
model appears highly interesting for future histopathological
and molecular studies. This will involve the establishment
of immunohistochemical markers that are distinctive in the
detection of different canine macrophage polarization stages (i.e.,
M1 and M2 macrophages). Moreover, integration of clinical
and pathologic data in order to get detailed insights into the
time course of immune responses and axonopathy, will provide
an opportunity to improve the prediction of outcome and
identify potential therapy targets. The same is true for the search
of biomarkers, where close integrative collaboration of basic
pathology science and research in the clinical setting will profit
from each other in order to identify predictive factors influencing
the course and outcome of IVDE-induced SCI.
The considerable paucity of pathologic data on chronic
and advanced disease stages demonstrates the necessity of
pathological investigations of such cases. This involves routine
sampling of spinal cord tissue during necropsy, also from cases
without an acute neurologic disease history from the side of
pathology and rigorous communication of anamnestic data, as
a considerable number of dogs might undergo necropsy due to
other acute diseases where spinal cord alterations subsequent to
IVDE years ago may be overseen.
Lastly, the pathogenesis of PMMas a devastating complication
of canine SCI, is incompletely understood. There are surprisingly
few studies on the pathology of this exacerbated form of
secondary injury. The ongoing development of a panel of
immunohistochemical methods for the detection of secondary
injury processes such as immune and glial response and axonal
damage including molecular alterations in research of canine
IVDE induced SCI provides a promising tool for investigations
on PMM. This will help to identify commonalities and differences
and potentially contribute to the identification of predictive
biomarkers and more detailed understanding of the pathogenesis
of PMM.
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